| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;96:29-32.)
© 1997 American Heart Association, Inc.
Articles |
Oral Sulfonylurea Hypoglycemic Agents Prevent Ischemic Preconditioning in Human Myocardium
Two Paradoxes Revisited
From the Department of Surgery, University of Colorado Health Sciences Center, Denver.
Correspondence to Joseph C. Cleveland, Jr, MD, University of Colorado Health Sciences Center, Department of Surgery, Box C-305, 4200 E Ninth Ave, Denver, CO 80262.
Background Patients receiving oral hypoglycemic agents for diabetes mellitus are at increased risk of cardiovascular mortality. Oral hypoglycemic agents are inhibitors of the ATP-sensitive potassium (KATP) channel. Ischemic preconditioning is mediated by KATP channel activation. We therefore hypothesized that myocardium from patients taking long-term oral hypoglycemic agents would be resistant to the protection by ischemic preconditioning.
Methods and Results Isolated human right atrial trabeculae were suspended in an organ bath at 37°C, with field stimulation at 1 Hz. Control trabeculae were then subjected to 45 minutes of simulated ischemia (hypoxic, glucose-free buffer with pacing at 3 Hz) and 120 minutes of reperfusion. Ischemic preconditioned (IPC) trabeculae from patients without oral hypoglycemic therapy and from patients taking insulin (Ins+IPC) were given 5 minutes of simulated ischemia before this injury. Trabeculae (Oral Hypo+IPC) were obtained from patients taking long-term oral hypoglycemic agents and were also exposed to 5 minutes of simulated ischemia before this injury. Developed force (DF) was recorded. Recovery of DF relative to preischemic values was 28±4% in control trabeculae, whereas IPC trabeculae showed 52±5% recovery (P<.05 versus control). In patients receiving long-term oral hypoglycemic agents (Oral Hypo+IPC), recovery of DF was 27±3%, but in trabeculae from insulin-treated patients (Ins+IPC), it was 45±6%.
Conclusions Human myocardium from patients without long-term exposure to oral hypoglycemic agents is functionally protected by preconditioning. Long-term oral hypoglycemic intake blocks the protection by preconditioning. These data suggest that ischemic preconditioning in human myocardium relies on KATP channels, and long-term inhibition of KATP channels with oral hypoglycemic agents may explain the excess cardiovascular mortality in these patients.
Key Words: diabetes mellitus • pharmacology • ischemia
This article has been cited by other articles:
 |
|
 |
|
  E. Golomb, A. Nyska, and H. Schwalb Occult Cardiotoxicity--Toxic Effects on Cardiac Ischemic Tolerance Toxicol Pathol, August 1, 2009; 37(5): 572 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Peart and J. P. Headrick Clinical cardioprotection and the value of conditioning responses Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1705 - H1720. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Arruda-Olson, R. K. Patch III, C. L. Leibson, A. Vella, R. L. Frye, S. A. Weston, J. M. Killian, and V. L. Roger Effect of Second-Generation Sulfonylureas on Survival in Patients With Diabetes Mellitus After Myocardial Infarction Mayo Clin. Proc., January 1, 2009; 84(1): 28 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Takahashi, Y Hiasa, Y Ohara, S Miyazaki, K Mahara, R Ogura, H Miyajima, K Yuba, N Suzuki, S Hosokawa, et al. Acute hyperglycaemia prevents the protective effect of pre-infarction angina on microvascular function after primary angioplasty for acute myocardial infarction Heart, November 1, 2008; 94(11): 1402 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ferdinandy, R. Schulz, and G. F. Baxter Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning Pharmacol. Rev., December 1, 2007; 59(4): 418 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. A. Ali, C. J. Callaghan, E. Lim, A. A. Ali, S.A. Reza Nouraei, A. M. Akthar, J. R. Boyle, K. Varty, R. K. Kharbanda, D. P. Dutka, et al. Remote Ischemic Preconditioning Reduces Myocardial and Renal Injury After Elective Abdominal Aortic Aneurysm Repair: A Randomized Controlled Trial Circulation, September 11, 2007; 116(11_suppl): I-98 - I-105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Riksen, Z. Zhou, W. J.G. Oyen, R. Jaspers, B. P. Ramakers, R. M.H.J. Brouwer, O. C. Boerman, N. Steinmetz, P. Smits, and G. A. Rongen Caffeine Prevents Protection in Two Human Models of Ischemic Preconditioning J. Am. Coll. Cardiol., August 15, 2006; 48(4): 700 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hassouna, M. Loubani, B. M. Matata, A. Fowler, N. B. Standen, and M. Galinanes Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium Cardiovasc Res, February 1, 2006; 69(2): 450 - 458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Imazio, M. Bobbio, E. Cecchi, D. Demarie, F. Pomari, M. Moratti, A. Ghisio, R. Belli, and R. Trinchero Colchicine as First-Choice Therapy for Recurrent Pericarditis: Results of the CORE (COlchicine for REcurrent pericarditis) Trial Arch Intern Med, September 26, 2005; 165(17): 1987 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Shanmuganathan, D. J. Hausenloy, M. R. Duchen, and D. M. Yellon Mitochondrial permeability transition pore as a target for cardioprotection in the human heart Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H237 - H242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Quast, D. Stephan, S. Bieger, and U. Russ The Impact of ATP-Sensitive K+ Channel Subtype Selectivity of Insulin Secretagogues for the Coronary Vasculature and the Myocardium Diabetes, December 1, 2004; 53(suppl_3): S156 - S164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.W. Broadhead, R.K. Kharbanda, M.J. Peters, and R.J. MacAllister KATP Channel Activation Induces Ischemic Preconditioning of the Endothelium in Humans In Vivo Circulation, October 12, 2004; 110(15): 2077 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Zaugg, M. C. Schaub, and P. Foex Myocardial injury and its prevention in the perioperative setting Br. J. Anaesth., July 1, 2004; 93(1): 21 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Steensrud, D. Nordhaug, K. V. Husnes, E. Aghajani, and D. G. Sorlie Replacing potassium with nicorandil in cold St. Thomas' Hospital cardioplegia improves preservation of energetics and function in pig hearts Ann. Thorac. Surg., April 1, 2004; 77(4): 1391 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF]
|
|
|
|
|
|
J J Meier, B Gallwitz, W E Schmidt, A Mugge, and M A Nauck Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? Heart, January 1, 2004; 90(1): 9 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schneider, N. Ad, U. Izhar, I. Khaliulin, J. B. Borman, and H. Schwalb Protection of myocardium by cyclosporin A and insulin: in vitro simulated ischemia study in human myocardium Ann. Thorac. Surg., October 1, 2003; 76(4): 1240 - 1245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub Anaesthetics and cardiac preconditioning. Part II. Clinical implications Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chachin, M. Yamada, A. Fujita, T. Matsuoka, K. Matsushita, and Y. Kurachi Nateglinide, a D-Phenylalanine Derivative Lacking Either a Sulfonylurea or Benzamido Moiety, Specifically Inhibits Pancreatic beta -Cell-Type KATP Channels J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1025 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Weintraub Impaired Hypoxic Coronary Vasodilation and ATP-Sensitive Potassium Channel Function: A Manifestation of Diabetic Microangiopathy in Humans? Circ. Res., February 7, 2003; 92(2): 127 - 129. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Riddle Sulfonylureas Differ in Effects on Ischemic Preconditioning--Is it Time to Retire Glyburide? J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 528 - 530. [Full Text] [PDF]
|
|
|
|
|
|
H. F del Valle, E. C Lascano, and J. A Negroni Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels Cardiovasc Res, August 15, 2002; 55(3): 642 - 659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Caulfield and K. D. O'Brien Cardiovascular Safety of Oral Antidiabetic Agents: The Insulin Secretagogues Clin. Diabetes, April 1, 2002; 20(2): 81 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Scognamiglio, A. Avogaro, S. Vigili de Kreutzenberg, C. Negut, M. Palisi, E. Bagolin, and A. Tiengo Effects of Treatment With Sulfonylurea Drugs or Insulin on Ischemia-Induced Myocardial Dysfunction in Type 2 Diabetes Diabetes, March 1, 2002; 51(3): 808 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Raeburn, J. C. Cleveland Jr, M. A. Zimmerman, and A. H. Harken Organ Preconditioning Arch Surg, November 1, 2001; 136(11): 1263 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C A Dinarello Novel targets for interleukin 18 binding protein Ann Rheum Dis, November 1, 2001; 60(90003): iii18 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Mocanu, H. L. Maddock, G. F. Baxter, C. L. Lawrence, N. B. Standen, and D. M. Yellon Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide Circulation, June 26, 2001; 103(25): 3111 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kersten, M. W. Montgomery, T. Ghassemi, E. R. Gross, W. G. Toller, P. S. Pagel, and D. C. Warltier Diabetes and hyperglycemia impair activation of mitochondrial KATP channels Am J Physiol Heart Circ Physiol, April 1, 2001; 280(4): H1744 - H1750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghosh, N. B. Standen, and M. Galinanes Failure to precondition pathological human myocardium J. Am. Coll. Cardiol., March 1, 2001; 37(3): 711 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kaneko, Y. Saito, Y. Hikawa, K. Yasuda, and K. Makita Dose-dependent prophylactic effect of nicorandil, an ATP-sensitive potassium channel opener, on intra-operative myocardial ischaemia in patients undergoing major abdominal surgery Br. J. Anaesth., March 1, 2001; 86(3): 332 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Pomerantz, L. L. Reznikov, A. H. Harken, and C. A. Dinarello Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta PNAS, February 27, 2001; 98(5): 2871 - 2876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. O'Rourke Myocardial KATP Channels in Preconditioning Circ. Res., November 10, 2000; 87(10): 845 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Yellon and A. Dana The Preconditioning Phenomenon : A Tool for the Scientist or a Clinical Reality? Circ. Res., September 29, 2000; 87(7): 543 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Gaudette, I. B. Krukenkamp, A. E. Saltman, H. Horimoto, and S. Levitsky Preconditioning with PKC and the ATP-sensitive potassium channels: a codependent relationship Ann. Thorac. Surg., August 1, 2000; 70(2): 602 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Pomerantz, T. N. Robinson, T. D. Morrell, J. K. Heimbach, A. Banerjee, and A. H. Harken Selective mitochondrial adenosine triphosphate-sensitive potassium channel activation is sufficient to precondition human myocardium J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 387 - 392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt, S. P. Marso, A. M. Lincoff, K. E. Wolski, S. G. Ellis, and E. J. Topol Abciximab reduces mortality in diabetics following percutaneous coronary intervention J. Am. Coll. Cardiol., March 15, 2000; 35(4): 922 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-H. Mak and E. J. Topol Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus J. Am. Coll. Cardiol., March 1, 2000; 35(3): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Chen, K. Y. Oh, A. Terzic, and J. C. Burnett Jr. The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure Eur J Heart Fail, March 1, 2000; 2(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Klamann, P Sarfert, V Launhardt, G Schulte, W.H Schmiegel, and M.A Nauck Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) Eur. Heart J., February 1, 2000; 21(3): 220 - 229. [Abstract] [PDF]
|
|
|
|
|
|
T. Shindo, Y. Katayama, Y. Horio, and Y. Kurachi MCC-134, a Novel Vascular Relaxing Agent, Is an Inverse Agonist for the Pancreatic-Type ATP-Sensitive K+ Channel J. Pharmacol. Exp. Ther., January 1, 2000; 292(1): 131 - 135. [Abstract] [Full Text]
|
|
|
|
|
|
S. Hu, S. Wang, and B. E. Dunning Tissue Selectivity of Antidiabetic Agent Nateglinide: Study on Cardiovascular and beta -Cell KATP Channels J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1372 - 1379. [Abstract] [Full Text]
|
|
|
|
|
|
D. Belhomme, J. Peynet, M. Louzy, J.-M. Launay, M. Kitakaze, and P. Menasche Evidence for Preconditioning by Isoflurane in Coronary Artery Bypass Graft Surgery Circulation, November 9, 1999; 100 (2009): II-340 - II-344. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Perrault and P. Menasche Preconditioning: can nature’s shield be raised against surgical ischemic-reperfusion injury? Ann. Thorac. Surg., November 1, 1999; 68(5): 1988 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tomai, F. Crea, L. Chiariello, and P. A. Gioffre Ischemic Preconditioning in Humans : Models, Mediators, and Clinical Relevance Circulation, August 3, 1999; 100(5): 559 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Tomai, A. Danesi, A.S. Ghini, F. Crea, M. Perino, A. Gaspardone, G. Ruggeri, L. Chiariello, and P.A. Gioffre Effects of KATPchannel blockade by glibenclamide on the warm-up phenomenon Eur. Heart J., February 1, 1999; 20(3): 196 - 202. [Abstract] [PDF]
|
|
|
|
|
|
K. N. Garratt, P. A. Brady, N. L. Hassinger, D. E. Grill, A. Terzic, and D. R. Holmes Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction J. Am. Coll. Cardiol., January 1, 1999; 33(1): 119 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Schotborgh and A. A.M. Wilde ATP-Sensitive Potassium Channel Openers and Blockers in the Cardiovascular System: Physiology, Pharmacology, and Clinical Effects Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 1998; 2(3): 243 - 255. [Abstract] [PDF]
|
|
|
|
|
|
B. S. Cain, D. R. Meldrum, K. S. Joo, J.-F. Wang, X. Meng, J. C. Cleveland Jr., A. Banerjee, and A. H. Harken Human SERCA2a levels correlate inversely with age in senescent human myocardium J. Am. Coll. Cardiol., August 1, 1998; 32(2): 458 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dana, J.-i. Imagawa, D. M Yellon, F. Tomai, F. Crea, A. Gaspardone, and P. A. Gioffre Phentolamine and Preconditioning During Coronary Angioplasty • Response Circulation, July 28, 1998; 98(4): 378 - 379. [Full Text]
|
|
|
|
|
|
T. C. Wascher, J. C. Cleveland, D. R. Meldrum, B. S. Cain, A. Banerjee, and A. H. Harken Sulfonylureas and Cardiovascular Mortality in Diabetes: A Class Effect? • Response Circulation, April 14, 1998; 97(14): 1427 - 1428. [Full Text]
|
|
|
|
|
|
B. S. Cain, D. R. Meldrum, X. Meng, B. D. Shames, A. Banerjee, and A. H. Harken Calcium Preconditioning in Human Myocardium Ann. Thorac. Surg., April 1, 1998; 65(4): 1065 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. Meldrum Tumor necrosis factor in the heart Am J Physiol Regulatory Integrative Comp Physiol, March 1, 1998; 274(3): R577 - R595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Nesto and S. Zarich Acute Myocardial Infarction in Diabetes Mellitus : Lessons Learned From ACE Inhibition Circulation, January 13, 1998; 97(1): 12 - 15. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yokoshiki, M. Sunagawa, T. Seki, and N. Sperelakis ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells Am J Physiol Cell Physiol, January 1, 1998; 274(1): C25 - C37. [Abstract] [Full Text] [PDF]
|
|